Masayuki Matsushita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masayuki Matsushita has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Hideki Matsui
Okayama University
2 shared publicationsAkira Hayasaka
Research Division, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan
1 shared publication- Asuka Ashikari
Univ Ryukyus, Grad Sch Med, Dept Urol, Nishihara, Okinawa, Japan
1 shared publication Atsuhiko Kato
Research Division, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan
1 shared publicationEriko Tanaka
Research Division, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., 200, Kajiwara, Kamakura, Kanagawa, 247-8530, Japan
1 shared publicationEtsuko Fujii
Research Division, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan
1 shared publication
Latest Publications
- Open Access
- 28 April 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 53 (8) , 1497-1505
Effect of a mobile digital intervention to enhance physical activity in individuals with metabolic disorders on voiding patterns measured by 24-h voided volume monitoring system: Kumejima Digital Health Project (KDHP)
Purpose: To evaluate the effect of a mobile digital intervention on voiding patterns, we performed 24-h voided volume monitoring in individuals with metabolic disorders. Methods: Participants with metabolic disorders were grouped into either the intervention group (n = 17), who had access to a smartphone app (CARADA), or the non-intervention group (n = 11), who did not. Urine monitoring was conducted for 24 h using a novel digital self-health monitoring system for urine excretion (s-HMSU). Body weight, abdominal circumference, blood pressure, and biomarkers were measured. Results: Physical findings and blood test results at baseline and 6 months indicated no significant between-group differences. Night-time frequency did not change between baseline and 6 months in the intervention group but significantly worsened at 6 months in the non-intervention group, as compared to baseline (1.0 ± 0.7 vs. 1.5 ± 0.5, p < 0.05). The change in night-time frequency over 6 months did not differ between the intervention and non-intervention groups. Furthermore, the change in hours of undisturbed sleep over 6 months did not differ between the two groups. However, compared with baseline, nocturnal polyuria index tended to worsen at 6 months in the non-intervention group. Conclusion: Our study results suggest that mobile digital intervention might be useful for behavioral therapy to improve night-time frequency and urine production and that s-HMSU might be beneficial for confirming the prevention of progress in individuals with metabolic disorders, which can aid in modifying lifestyle.
- 28 April 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 53 (8) , 1497-1505
Open AccessEffect of a mobile digital intervention to enhance physical activity in individuals with metabolic disorders on voiding patterns measured by 24-h voided volume monitoring system: Kumejima Digital Health Project (KDHP)
Purpose: To evaluate the effect of a mobile digital intervention on voiding patterns, we performed 24-h voided volume monitoring in individuals with metabolic disorders. Methods: Participants with metabolic disorders were grouped into either the intervention group (n = 17), who had access to a smartphone app (CARADA), or the non-intervention group (n = 11), who did not. Urine monitoring was conducted for 24 h using a novel digital self-health monitoring system for urine excretion (s-HMSU). Body weight, abdominal circumference, blood pressure, and biomarkers were measured. Results: Physical findings and blood test results at baseline and 6 months indicated no significant between-group differences. Night-time frequency did not change between baseline and 6 months in the intervention group but significantly worsened at 6 months in the non-intervention group, as compared to baseline (1.0 ± 0.7 vs. 1.5 ± 0.5, p < 0.05). The change in night-time frequency over 6 months did not differ between the intervention and non-intervention groups. Furthermore, the change in hours of undisturbed sleep over 6 months did not differ between the two groups. However, compared with baseline, nocturnal polyuria index tended to worsen at 6 months in the non-intervention group. Conclusion: Our study results suggest that mobile digital intervention might be useful for behavioral therapy to improve night-time frequency and urine production and that s-HMSU might be beneficial for confirming the prevention of progress in individuals with metabolic disorders, which can aid in modifying lifestyle.
- Open Access
- 1 December 2020
- Published by Elsevier in Cell Reports
- Vol. 33 (12) , 108542
Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment
- 1 December 2020
- Published by Elsevier in Cell Reports
- Vol. 33 (12) , 108542
Open AccessExploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment
- 10 February 2005
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 83 (5) , 324-328
Protein transduction technology
With the elucidation of the human genome, exhaustive analysis of genomic data related to gene transcription and the structure and function of translated protein products has progressed rapidly. Delivery of proteins and their functional domains or inhibitory peptides directly into the cell is ideal to use this protein information and analyze associated physiological functions. Protein transduction technology, which controls cell function via direct delivery of a desired protein into the cell, involves fusing the protein with a special peptide sequence consisting of 10–20 amino acids, referred to as the protein transduction domain. The recent discovery that the protein transduction domain can also be inserted into various macromolecules heightens expectations in terms of development of novel advanced experimental tools and clinical reagents
- 10 February 2005
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 83 (5) , 324-328
Protein transduction technology
With the elucidation of the human genome, exhaustive analysis of genomic data related to gene transcription and the structure and function of translated protein products has progressed rapidly. Delivery of proteins and their functional domains or inhibitory peptides directly into the cell is ideal to use this protein information and analyze associated physiological functions. Protein transduction technology, which controls cell function via direct delivery of a desired protein into the cell, involves fusing the protein with a special peptide sequence consisting of 10–20 amino acids, referred to as the protein transduction domain. The recent discovery that the protein transduction domain can also be inserted into various macromolecules heightens expectations in terms of development of novel advanced experimental tools and clinical reagents
- Open Access
- 1 January 1998
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 22 (2) , 199-203
M-RIP, a novel target of JNK signaling and a requirement for human cancer cell invasion
Cell motility is involved in physiological and pathological processes such as the invasion and migration of cells. c-Jun N-terminal kinase (JNK) cascades are involved in the invasion and metastasis of cancer cells. However, little is known about the downstream signaling of JNK. In the present study, we used small interfering RNA (siRNA) directed against JNK1 to reduce its expression. We used microarray techniques to compare the gene expression profiles of epidermal growth factor (EGF)-stimulated HeLa cells with and without JNK1 siRNA treatment. We identified a JNK1 target gene, myosin phosphatase-Rho interacting protein (M-RIP). RNA interference-mediated inhibition of JNK1 strongly inhibited M-RIP mRNA expression induced by EGF, as well as the invasion of HeLa cells. In addition, M-RIP siRNA-treated cells showed significantly reduced invasive activity. Thus, a functional analysis of JNK1 and M-RIP with RNA interference reveals a critical role for this cascade in the invasive behavior of cancer cells.
- 1 January 1998
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 22 (2) , 199-203
Open AccessM-RIP, a novel target of JNK signaling and a requirement for human cancer cell invasion
Cell motility is involved in physiological and pathological processes such as the invasion and migration of cells. c-Jun N-terminal kinase (JNK) cascades are involved in the invasion and metastasis of cancer cells. However, little is known about the downstream signaling of JNK. In the present study, we used small interfering RNA (siRNA) directed against JNK1 to reduce its expression. We used microarray techniques to compare the gene expression profiles of epidermal growth factor (EGF)-stimulated HeLa cells with and without JNK1 siRNA treatment. We identified a JNK1 target gene, myosin phosphatase-Rho interacting protein (M-RIP). RNA interference-mediated inhibition of JNK1 strongly inhibited M-RIP mRNA expression induced by EGF, as well as the invasion of HeLa cells. In addition, M-RIP siRNA-treated cells showed significantly reduced invasive activity. Thus, a functional analysis of JNK1 and M-RIP with RNA interference reveals a critical role for this cascade in the invasive behavior of cancer cells.
- 1 May 1990
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 9 (2) , 163-168
Long-term effects of bezafibrate on in vivo VLDL-triglyceride production in the rat
- 1 May 1990
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 9 (2) , 163-168
Long-term effects of bezafibrate on in vivo VLDL-triglyceride production in the rat